Log in or register to see all Alerts
New HTA Decisions in Scotland
December 2021
Drug name
ORFADIN® (nitisinone)
Swedish Orphan Biovitrum
Decision date
Therapeutic area
Genetic conditions
Therapeutic sub area
Genetic conditions: general and other
Not recommended
Treatment of adult patients with alkaptonuria (AKU).
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, nitisinone (Orfadin®) is not recommended for use within NHS Scotland.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result it cannot be recommended for use within NHS Scotland.